

2 November 2023

Wholly owned subsidiary Mernova Medicinal Inc. achieves a record sales month in October with A\$899,512 of revenue, already has commitments of A\$602,836 for November.

Highlights:

- New purchase orders ('PO') totalling A\$1,502,348 (C\$1,306,390ⁱ) secured from provincial partners – expected to be delivered and recognised as revenue in Q4 FY2023
- October's POs totalled A\$899,512 (C\$782,184), a record month for Mernova surpassing every other month since inception
- Record October revenues follow strong sales growth during Q3 FY2023 of A\$1.849m (C\$1,579,130) – a 104% YoY increase on Q3 FY2022 (Q3 FY2022 sales: A\$907,742)
- October's strong performance to be carried over into November, with A\$602,836 (C\$524,205) worth of POs in commitments already received for the month
- Work is being undertaken to replicate the strong growth and traction in Nova Scotia through other Canadian provinces – revenue growth expected to continue over coming months.

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that wholly owned Canadian subsidiary, Mernova Medicinal Inc. ('Mernova') has secured several purchase orders to underpin Q4 FY2023 revenue, as well as generated its highest ever monthly sales since inception.

A\$899,512 in new POs highlight a record month for Mernova in October 2023:

During the month of October, Mernova received A\$899,512 (C\$782,184ⁱⁱ) worth of purchase orders for its dried cannabis flower, pre-roll joints and electronic vaporiser products which are sold under Mernova's established 'Ritual' brand. The orders, which were delivered during the month of October, will be recorded as revenue during Q4 FY2023.

The record-setting month of sales included an order of A\$573,873 (C\$499,020ⁱ) from the Nova Scotia Liquor Corporation ('NSLC'), highlighting the ongoing momentum that Mernova is generating in the region, which is currently the Company's largest sales generating province.

Mernova already has commitments in place for the month of November worth A\$602,836 (C\$524,205) and expects to receive additional POs during Q4 FY2023.

Management commentary:

Managing Director for Mernova, Mrs. Micheline Mackay said: *"I am incredibly pleased to see the ongoing increases in purchase orders to our growing business unit and record monthly sales. Our current inventory is moving very quickly, and we expect to be able to deliver further growth in Q4."*

Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: 613-581-6319

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.

ⁱ Based on a CAD to AUD FX rate of \$1.15

ⁱⁱ Based on a CAD to AUD FX rate of \$1.15